Special Issue

Design, Synthesis and Biological Testing of Next Generation Theranostic Radiopharmaceuticals

Message from the Guest Editor

In recent years, the radiopharmaceutical field has witnessed a surge in interest. This has, in particular, been spurred on by the successes of new drugs for targeted radionuclide therapy in oncology, such as PSMA-targeted compounds. In this sense. "theranostics" refers to the use of the same chemical targeting vector or delivery system, but labeled with either a diagnostic or a therapeutic radionuclide. The diagnostic variant will first detect disease through imaging techniques such as PET imaging, and verify that the targeting vector accumulates as desired. Second, the therapeutic variant will strike and eradicate the same lesions, with the diagnostic variant monitoring the efficacy of the therapy. With this, researchers are invited to submit original and review articles of a basic, preclinical and clinical scope, focusing on the design, synthesis and biological testing of new radiotheranostic compounds and delivery systems, and their future potential. Work that only focuses on diagnostics or therapy should have a clear potential application in theranostics. Accepted submissions will be published in this Special Issue of Pharmaceuticals.

Guest Editor

Dr. Andreas Ingemann Jensen

Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark

Deadline for manuscript submissions

closed (30 July 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/87185

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

